Celgene (CELG) Presents Data from Two AML-001 Sub-Group Analyses at ASH
Tweet Send to a Friend
Celgene (NASDAQ: CELG) announced that data from two sub-group analyses from AML-001, its phase III study of VIDAZA (azacitidine for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
